Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase
| Autor: | Richard M, Bergenstal, William V, Tamborlane, Andrew, Ahmann, John B, Buse, George, Dailey, Stephen N, Davis, Carol, Joyce, Bruce A, Perkins, John B, Welsh, Steven M, Willi, Michael A, Wood |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Blood Glucose Glycated Hemoglobin Male Cross-Over Studies genetic structures Adolescent Injections Subcutaneous Emerging Treatments and Technologies Middle Aged Young Adult Diabetes Mellitus Type 1 Insulin Infusion Systems Treatment Outcome Hyperglycemia Humans Hypoglycemic Agents Insulin Female Child Aged Original Research |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 |
| Popis: | OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months’ sustained use of SAP. RESEARCH DESIGN AND METHODS The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|